PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
3.16%
Revenue growth under 50% of CVE's 7.28%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
-17.99%
Negative gross profit growth while CVE is at 11.53%. Joel Greenblatt would examine cost competitiveness or demand decline.
-56.00%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-56.00%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-89.54%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-90.63%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-90.63%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.03%
Share count expansion well above CVE's 0.03%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
No Data
No Data available this quarter, please select a different quarter.
-0.36%
Dividend reduction while CVE stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
37.95%
OCF growth under 50% of CVE's 78.31%. Michael Burry might suspect questionable revenue recognition or rising costs.
55.02%
FCF growth under 50% of CVE's 195.39%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
65.93%
10Y CAGR of 65.93% while CVE is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
94.28%
5Y CAGR of 94.28% while CVE is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
6.58%
3Y CAGR of 6.58% while CVE is zero. Bruce Berkowitz would see if small gains can accelerate to a more decisive lead.
No Data
No Data available this quarter, please select a different quarter.
213.68%
OCF/share CAGR of 213.68% while CVE is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
75.55%
3Y OCF/share CAGR of 75.55% while CVE is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
-90.22%
Negative 10Y net income/share CAGR while CVE is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-92.17%
Negative 5Y net income/share CAGR while CVE is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-98.02%
Negative 3Y CAGR while CVE is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
575.59%
Equity/share CAGR of 575.59% while CVE is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
154.17%
Equity/share CAGR of 154.17% while CVE is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
45.39%
Equity/share CAGR of 45.39% while CVE is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
723.35%
Dividend/share CAGR of 723.35% while CVE is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
303.91%
3Y dividend/share CAGR of 303.91% while CVE is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
7.14%
AR growth of 7.14% while CVE is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
2.39%
Inventory growth of 2.39% while CVE is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
9.58%
Asset growth of 9.58% while CVE is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
2.91%
BV/share growth of 2.91% while CVE is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
59.39%
Debt growth of 59.39% while CVE is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
No Data
No Data available this quarter, please select a different quarter.
20.83%
SG&A declining or stable vs. CVE's 367.31%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.